TAFRO syndrome: A disease that known is half cured

被引:14
作者
Chen, Tingting [1 ]
Feng, Chun [1 ,2 ,3 ]
Zhang, Xinyou [1 ,2 ,3 ]
Zhou, Jihao [1 ,2 ,3 ]
机构
[1] Jinan Univ, Clin Med Coll 2, Dept Hematol, Shenzhen, Guangdong, Peoples R China
[2] Shenzhen Peoples Hosp, Dept Hematol, 1017 Dongmen North Rd, Shenzhen 518000, Guangdong, Peoples R China
[3] Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
clinical diagnostic criteria; cytokine storm; etiology; pathogenesis; TAFRO syndrome; treatment management; MULTICENTRIC CASTLEMANS-DISEASE; DIAGNOSTIC-CRITERIA; CYCLOSPORINE-A; CASE SERIES; TOCILIZUMAB; THROMBOCYTOPENIA; SILTUXIMAB; ANASARCA; ASCITES; PATIENT;
D O I
10.1002/hon.3075
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly (TAFRO) syndrome is rare in clinical practice. It is a systemic inflammatory disease caused by a cytokine storm. Its clinical manifestations include thrombocytopenia, systemic edema, fever, bone marrow fibrosis, renal insufficiency, and organ enlargement. The high mortality rate of TAFRO syndrome is due to the difficulty of acquiring biopsy samples for diagnosis and the rapid disease progression. This disease is poorly understood by clinicians. Early detection, accurate diagnosis, and timely treatment play key roles in prolonging the survival of the patients. This review summarizes the latest progress in the pathogenesis, diagnostic criteria, and treatment regimens of TAFRO syndrome, aiming to help clinicians better understand TAFRO syndrome and improve its diagnosis and treatment.
引用
收藏
页码:310 / 322
页数:13
相关论文
共 121 条
[1]   Glycogen synthase kinase 3β/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO [J].
Abe, Nobuya ;
Kono, Michihito ;
Kono, Michihiro ;
Ohnishi, Naoki ;
Sato, Tomoya ;
Tarumi, Masato ;
Yoshimura, Masaru ;
Sato, Taiki ;
Karino, Kohei ;
Shimizu, Yuka ;
Fujieda, Yuichiro ;
Kato, Masaru ;
Hasebe, Rie ;
Oku, Kenji ;
Murakami, Masaaki ;
Atsumi, Tatsuya .
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (05) :1194-1204
[2]   In silico Insights on IL-6: A Potential Target for Multicentric Castleman Disease [J].
Aher, Abhishek ;
Udhwani, Trishang ;
Khandelwal, Ravina ;
Limaye, Aakanksha ;
Hussain, Tajamul ;
Nayarisseri, Anuraj ;
Singh, Sanjeev Kumar .
CURRENT COMPUTER-AIDED DRUG DESIGN, 2020, 16 (05) :641-653
[3]   Intracranial Hemorrhage in a Patient with TAFRO Syndrome Treated with Cyclosporine A and Rituximab [J].
Akagi, Yuina ;
Kato, Takashi ;
Yamashita, Yusuke ;
Hosoi, Hiroki ;
Murata, Shogo ;
Yamamoto, Shuto ;
Warigaya, Kenji ;
Nakao, Taisei ;
Murata, Shinichi ;
Sonoki, Takashi ;
Tamura, Shinobu .
MEDICINA-LITHUANIA, 2021, 57 (09)
[4]   Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review [J].
Akiyama, Mitsuhiro ;
Kaneko, Yuko ;
Takeuchi, Tsutomu .
ANNALS OF HEMATOLOGY, 2020, 99 (11) :2463-2475
[5]   Tocilizumab-resistant TAFRO Syndrome Complicated by Type II Respiratory Failure [J].
Aoki, Tatsuya ;
Wada, Mikio ;
Kawashima, Atsushi ;
Hirakawa, Kouichi ;
Nagata, Akihiro ;
Kagawa, Keizo .
INTERNAL MEDICINE, 2017, 56 (23) :3249-3254
[6]   Increased mTOR activation in idiopathic multicentric Castleman disease [J].
Arenas, Daniel J. ;
Floess, Katherine ;
Kobrin, Dale ;
Pai, Ruth-Anne Langan ;
Srkalovic, Maya B. ;
Tamakloe, Mark-Avery ;
Rasheed, Rozena ;
Ziglar, Jasira ;
Khor, Johnson ;
Parente, Sophia A. T. ;
Pierson, Sheila K. ;
Martinez, Daniel ;
Wertheim, Gerald B. ;
Kambayashi, Taku ;
Baur, Joseph ;
Teachey, David T. ;
Fajgenbaum, David C. .
BLOOD, 2020, 135 (19) :1673-1684
[7]  
Barozzi P, 1996, J CLIN PATHOL-CL MOL, V49, pM232
[8]   Castleman disease [J].
Carbone, Antonino ;
Borok, Margaret ;
Damania, Blossom ;
Gloghini, Annunziata ;
Polizzotto, Mark N. ;
Jayanthan, Raj K. ;
Fajgenbaum, David C. ;
Bower, Mark .
NATURE REVIEWS DISEASE PRIMERS, 2021, 7 (01)
[9]  
CASTLEMAN B, 1954, NEW ENGL J MED, V251, P107
[10]   mTOR signaling as a driver of Castleman disease [J].
Colgan, John D. .
BLOOD, 2020, 135 (19) :1614-1615